Dr. Patel on a Subgroup Analysis of the NAPOLI-1 Trial in Pancreatic Cancer

Reema A. Patel, MD, discusses the results of a subgroup analysis from the NAPOLI-1 trial in pancreatic cancer.

Reema A. Patel, MD, associate program director, Hematology & Medical Oncology Fellowship, assistant professor of medicine, Division of Medical Oncology, University of Kentucky, discusses the results of a subgroup analysis from the NAPOLI-1 trial in pancreatic cancer.

The phase 3 NAPOLI-1 trial demonstrated a survival benefit with liposomal irinotecan (Onivyde) in combination with 5-fluorouracil (5-FU) and leucovorin versus 5-FU and leucovorin alone in patients with metastatic pancreatic ductal adenocarcinoma who had received prior gemcitabine-based therapy.

A post-hoc subgroup analysis revealed that the majority of patient subgroups responded well to the treatment, Patel explains. However, patients who received prior non-liposomal irinotecan had poorer outcomes versus patients who had no prior irinotecan. Notably, due to the low number of patients who had prior non-liposomal irinotecan, these findings may not be widely applicable in the real-world setting, Patel says.

However, in practice, it may be optimal to give an alternative therapy between non-liposomal irinotecan and liposomal irinotecan to potentially increase the chance of response to liposomal irinotecan, concludes Patel.

Related Videos
Paolo Tarantino, MD
Aditya Bardia, MD, MPH, FASCO
Giuseppe Curigliano, MD, PhD, director, Early Drug Development Division, co-chair, Experimental Therapeutics Program, the European Institute of Oncology
Mina Lobbous, MD, MPH
Noa Biran, MD
Andrew Hantel, MD
Peter Forsyth, MD
Jakub Svoboda, MD
Joaquim Bellmunt, MD, PhD
María-Victoria Mateos, MD, PhD